Christian Stratz1, Timo Bömicke2, Iris Younas2, Anja Kittel3, Michael Amann2, Christian M Valina2, Thomas Nührenberg2, Dietmar Trenk2, Franz-Josef Neumann2, Willibald Hochholzer2. 1. University Heart Center Freiburg Bad Krozingen, Department of Cardiology and Angiology II, Bad Krozingen, Germany. Electronic address: christian.stratz@universitaets-herzzentrum.de. 2. University Heart Center Freiburg Bad Krozingen, Department of Cardiology and Angiology II, Bad Krozingen, Germany. 3. Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich-Alexander-Universitaet Erlangen-Nüernberg, Erlangen, Germany.
Abstract
BACKGROUND: Previous data suggest that reticulated platelets significantly affect antiplatelet response to thienopyridines. It is unknown whether parameters describing reticulated platelets can predict antiplatelet response to thienopyridines. OBJECTIVES: The authors sought to determine the extent to which parameters describing reticulated platelets can predict antiplatelet response to thienopyridine loading compared with established predictors. METHODS: This study randomized 300 patients undergoing elective coronary stenting to loading withclopidogrel 600 mg, prasugrel 30 mg, or prasugrel 60 mg. Adenosine diphosphate (ADP)-induced platelet reactivity was assessed by impedance aggregometry before loading (intrinsic platelet reactivity) and again on day 1 after loading. Multiple parameters of reticulated platelets were assessed by automated whole blood flow cytometry: absolute immature platelet count (IPC), immature platelet fraction, and highly fluorescent immature platelet fraction. RESULTS: Each parameter of reticulated platelets correlated significantly with ADP-induced platelet reactivity (p < 0.01 for all 3 parameters). In a multivariable model including all 3 parameters, only IPC remained a significant predictor of platelet reactivity (p < 0.001). In models adjusting each of the 3 parameters for known predictors of on-treatment platelet reactivity including cytochrome P450 2C19 (CYP2C19) polymorphisms, age, body mass index, diabetes, and intrinsic platelet reactivity, only IPC prevailed as an independent predictor (p = 0.001). In this model, IPC was the strongest predictor of on-treatment platelet reactivity followed by intrinsic platelet reactivity. CONCLUSIONS: IPC is the strongest independent platelet count-derived predictor of antiplatelet response to thienopyridine treatment. Given its easy availability, together with its even stronger association with on-treatment platelet reactivity compared with known predictors, including the CYP2C19*2 polymorphism, IPC may become the preferred predictor of antiplatelet response to thienopyridine treatment. (Impact of Extent of Clopidogrel-Induced Platelet Inhibition During Elective Stent Implantation on Clinical Event Rate-Advanced Loading Strategies [ExcelsiorLOAD]; DRKS00006102).
RCT Entities:
BACKGROUND: Previous data suggest that reticulated platelets significantly affect antiplatelet response to thienopyridines. It is unknown whether parameters describing reticulated platelets can predict antiplatelet response to thienopyridines. OBJECTIVES: The authors sought to determine the extent to which parameters describing reticulated platelets can predict antiplatelet response to thienopyridine loading compared with established predictors. METHODS: This study randomized 300 patients undergoing elective coronary stenting to loading with clopidogrel 600 mg, prasugrel 30 mg, or prasugrel 60 mg. Adenosine diphosphate (ADP)-induced platelet reactivity was assessed by impedance aggregometry before loading (intrinsic platelet reactivity) and again on day 1 after loading. Multiple parameters of reticulated platelets were assessed by automated whole blood flow cytometry: absolute immature platelet count (IPC), immature platelet fraction, and highly fluorescent immature platelet fraction. RESULTS: Each parameter of reticulated platelets correlated significantly with ADP-induced platelet reactivity (p < 0.01 for all 3 parameters). In a multivariable model including all 3 parameters, only IPC remained a significant predictor of platelet reactivity (p < 0.001). In models adjusting each of the 3 parameters for known predictors of on-treatment platelet reactivity including cytochrome P450 2C19 (CYP2C19) polymorphisms, age, body mass index, diabetes, and intrinsic platelet reactivity, only IPC prevailed as an independent predictor (p = 0.001). In this model, IPC was the strongest predictor of on-treatment platelet reactivity followed by intrinsic platelet reactivity. CONCLUSIONS:IPC is the strongest independent platelet count-derived predictor of antiplatelet response to thienopyridine treatment. Given its easy availability, together with its even stronger association with on-treatment platelet reactivity compared with known predictors, including the CYP2C19*2 polymorphism, IPC may become the preferred predictor of antiplatelet response to thienopyridine treatment. (Impact of Extent of Clopidogrel-Induced Platelet Inhibition During Elective Stent Implantation on Clinical Event Rate-Advanced Loading Strategies [ExcelsiorLOAD]; DRKS00006102).
Authors: Michael J Kraakman; Man Ks Lee; Annas Al-Sharea; Dragana Dragoljevic; Tessa J Barrett; Emilie Montenont; Debapriya Basu; Sarah Heywood; Helene L Kammoun; Michelle Flynn; Alexandra Whillas; Nordin Mj Hanssen; Mark A Febbraio; Erik Westein; Edward A Fisher; Jaye Chin-Dusting; Mark E Cooper; Jeffrey S Berger; Ira J Goldberg; Prabhakara R Nagareddy; Andrew J Murphy Journal: J Clin Invest Date: 2017-05-15 Impact factor: 14.808
Authors: Adi Lador; Dorit Leshem-Lev; Galia Spectre; Aryeh Abelow; Ran Kornowski; Eli I Lev Journal: J Thromb Thrombolysis Date: 2017-10 Impact factor: 2.300
Authors: Muataz Ali Hamad; Krystin Krauel; Nancy Schanze; Nadine Gauchel; Peter Stachon; Thomas Nuehrenberg; Mark Zurek; Daniel Duerschmied Journal: Front Cardiovasc Med Date: 2022-04-07
Authors: Matthias K Freynhofer; Liana Iliev; Veronika Bruno; Miklos Rohla; Florian Egger; Thomas W Weiss; Wolfgang Hübl; Martin Willheim; Johann Wojta; Kurt Huber Journal: Thromb Haemost Date: 2017-02-23 Impact factor: 5.249
Authors: Thomas G Nührenberg; Jasmin Stöckle; Federico Marini; Mark Zurek; Björn A Grüning; Vladimir Benes; Lutz Hein; Franz-Josef Neumann; Christian Stratz; Marco Cederqvist; Willibald Hochholzer Journal: PLoS One Date: 2022-01-27 Impact factor: 3.240
Authors: Amir Cohen; Emanuel Harari; Michal Cipok; Avishag Laish-Farkash; Gabriel Bryk; Ella Yahud; Yaron Sela; Nili Karp Lador; Tal Mann; Ami Mayo; Eli I Lev Journal: J Thromb Thrombolysis Date: 2020-09-30 Impact factor: 2.300